With $100 million in funding, Dianthus Therapeutics is on a mission to reduce the number of injections autoimmune disease patients have to receive.

Magenta Therapeutics and Dianthus Therapeutics announced a merger to form a company that will advance the latter’s next-generation complement inhibitor pipeline. The combined company will take on the ...

A new biotech startup by the name of Dianthus Therapeutics is launching with the goal of making drugs for autoimmune disorders a little less burdensome.

Across the recent three months, 5 analysts have shared their insights on Dianthus Therapeutics DNTH, expressing a variety of opinions spanning from bullish to bearish. The table below provides a ...

Magenta is hoisting Dianthus onto Wall Street via reverse merger months after the former announced it was on the hunt for a sale.

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -2.33% and -84.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for ...

Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency.

Dianthus Therapeutics, Inc. (DNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotech developing therapies for autoimmune neuromuscular diseases, reported second quarter results on August 7, 2025.